286 related articles for article (PubMed ID: 27498393)
1. Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer.
Suman S; Basak T; Gupta P; Mishra S; Kumar V; Sengupta S; Shukla Y
J Proteomics; 2016 Oct; 148():183-93. PubMed ID: 27498393
[TBL] [Abstract][Full Text] [Related]
2. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes.
Gajbhiye A; Dabhi R; Taunk K; Jagadeeshaprasad MG; RoyChoudhury S; Mane A; Bayatigeri S; Chaudhury K; Santra MK; Rapole S
J Proteomics; 2017 Jun; 163():1-13. PubMed ID: 28495502
[TBL] [Abstract][Full Text] [Related]
3. Identifying potential markers in Breast Cancer subtypes using plasma label-free proteomics.
Corrêa S; Panis C; Binato R; Herrera AC; Pizzatti L; Abdelhay E
J Proteomics; 2017 Jan; 151():33-42. PubMed ID: 27498391
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
5. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G
Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595
[TBL] [Abstract][Full Text] [Related]
6. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
El Ansari R; Craze ML; Miligy I; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res; 2018 Mar; 20(1):21. PubMed ID: 29566741
[TBL] [Abstract][Full Text] [Related]
7. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
Metzger-Filho O; Sun Z; Viale G; Price KN; Crivellari D; Snyder RD; Gelber RD; Castiglione-Gertsch M; Coates AS; Goldhirsch A; Cardoso F
J Clin Oncol; 2013 Sep; 31(25):3083-90. PubMed ID: 23897954
[TBL] [Abstract][Full Text] [Related]
8. Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers.
Pendharkar N; Gajbhiye A; Taunk K; RoyChoudhury S; Dhali S; Seal S; Mane A; Abhang S; Santra MK; Chaudhury K; Rapole S
J Proteomics; 2016 Jan; 132():112-30. PubMed ID: 26642762
[TBL] [Abstract][Full Text] [Related]
9. Protein Corona Gold Nanoparticles Fingerprinting Reveals a Profile of Blood Coagulation Proteins in the Serum of HER2-Overexpressing Breast Cancer Patients.
Chantada-Vázquez MDP; Castro López A; García-Vence M; Acea-Nebril B; Bravo SB; Núñez C
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182810
[TBL] [Abstract][Full Text] [Related]
10. The association between body mass index and immunohistochemical subtypes in breast cancer.
Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
[TBL] [Abstract][Full Text] [Related]
11. [Expression of chemokine CXCL12 and its receptor (CXCR4 and CXCR7) in different molecular subtypes of human breast carcinoma and the clinical significance].
Wu W; Qian L; Dai J; Ding B; Chen X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Feb; 42(2):147-153. PubMed ID: 28255115
[TBL] [Abstract][Full Text] [Related]
12. Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients.
Pacheco-Velázquez SC; Gallardo-Pérez JC; Aguilar-Ponce JL; Villarreal P; Ruiz-Godoy L; Pérez-Sánchez M; Marín-Hernández A; Ruiz-García E; Meneses-García A; Moreno-Sánchez R; Rodríguez-Enríquez S
Int J Oncol; 2014 Dec; 45(6):2549-59. PubMed ID: 25270118
[TBL] [Abstract][Full Text] [Related]
13. Label-free proteomic analysis of breast cancer molecular subtypes.
Panis C; Pizzatti L; Herrera AC; Corrêa S; Binato R; Abdelhay E
J Proteome Res; 2014 Nov; 13(11):4752-72. PubMed ID: 25221861
[TBL] [Abstract][Full Text] [Related]
14. Identification of
Zou J; Chen Y; Ji Z; Liu D; Chen X; Chen M; Chen K; Lin H; Chen Y; Li Z
Transl Cancer Res; 2024 Jan; 13(1):25-45. PubMed ID: 38410217
[TBL] [Abstract][Full Text] [Related]
15. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
El Ansari R; Craze ML; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Apr; 118(8):1115-1122. PubMed ID: 29545595
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
[TBL] [Abstract][Full Text] [Related]
17. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice.
Lim YJ; Lee SW; Choi N; Kwon J; Eom KY; Kang E; Kim EK; Kim SW; Kim JH; Kim YJ; Kim SH; Park SY; Kim JS; Kim IA
Breast Cancer Res Treat; 2017 Jun; 163(3):555-563. PubMed ID: 28315066
[TBL] [Abstract][Full Text] [Related]
18. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
19. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
Michaelidou K; Ardavanis A; Scorilas A
Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
